MESOTHELIOMA

This study tested two immunotherapy drugs, durvalumab and tremelimumab, in people with malignant pleural mesothelioma whose cancer had worsened after chemotherapy. The goal was to see if the combination could shrink tumors. The trial was stopped early after enrolling 19 participa…

This early-phase study tested a new drug called INCB099318 in 105 people with advanced solid tumors that had stopped responding to standard treatments. The main goal was to check the drug's safety and how the body processes it. The study was terminated early, so results are limit…

This early-stage study tested a new drug called SO-C101, either alone or with another drug (pembrolizumab), in 115 people with advanced solid tumors like lung, kidney, or skin cancer. The main goal was to check safety and find the right dose. The study was stopped early, so resul…

This study tested a new drug called TAK-500, given alone or with another drug (pembrolizumab), in 61 adults with advanced solid tumors like pancreatic, liver, and lung cancer. The main goals were to check safety and see if the drug could shrink tumors. The study was stopped early…

This study aimed to collect tumor tissue within hours after death from people with advanced lung, bladder, ovarian, or other cancers, as well as those who had adoptive cell therapy. Participants received inpatient hospice care at the NIH Clinical Center. The goal was to study how…